Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
8.17
+0.14 (1.74%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Zenas BioPharma Revenue
In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%. Zenas BioPharma had revenue of $5.00M in the quarter ending December 31, 2024.
Revenue (ttm)
$5.00M
Revenue Growth
-90.00%
P/S Ratio
21.57
Revenue / Employee
$38,462
Employees
130
Market Cap
341.50M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 8 days ago - Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress - Benzinga
- 11 days ago - Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 4 months ago - Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - GlobeNewsWire
- 5 months ago - Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 6 months ago - Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering - GlobeNewsWire